ATE302411T1 - Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens - Google Patents

Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens

Info

Publication number
ATE302411T1
ATE302411T1 AT01935666T AT01935666T ATE302411T1 AT E302411 T1 ATE302411 T1 AT E302411T1 AT 01935666 T AT01935666 T AT 01935666T AT 01935666 T AT01935666 T AT 01935666T AT E302411 T1 ATE302411 T1 AT E302411T1
Authority
AT
Austria
Prior art keywords
disease
crohn
prophylaxis
diagnosis
treatment
Prior art date
Application number
AT01935666T
Other languages
English (en)
Inventor
Stephan R Targan
Jonathan Braun
Christopher L Sutton
Original Assignee
Cedars Sinai Medical Center
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Univ California filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ATE302411T1 publication Critical patent/ATE302411T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/395—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Saccharomyces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01935666T 2000-05-19 2001-05-17 Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens ATE302411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/575,061 US7138237B1 (en) 2000-05-19 2000-05-19 Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
PCT/US2001/016032 WO2001089361A2 (en) 2000-05-19 2001-05-17 Diagnosis, prevention and treatment of crohn's disease using the ompc antigen

Publications (1)

Publication Number Publication Date
ATE302411T1 true ATE302411T1 (de) 2005-09-15

Family

ID=24298769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01935666T ATE302411T1 (de) 2000-05-19 2001-05-17 Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens

Country Status (8)

Country Link
US (4) US7138237B1 (de)
EP (1) EP1285271B1 (de)
JP (1) JP4917728B2 (de)
AT (1) ATE302411T1 (de)
AU (1) AU2001261741A1 (de)
DE (1) DE60112744T2 (de)
ES (1) ES2247115T3 (de)
WO (1) WO2001089361A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20040076960A1 (en) * 2002-10-18 2004-04-22 Taylor Kent D. Methods of using a NOD2/CARD15 haplotype to diagnose Crohn's disease
US7018188B2 (en) 2003-04-08 2006-03-28 The Procter & Gamble Company Apparatus for forming fibers
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
CA2519696A1 (en) * 2003-04-11 2004-10-28 Cedars-Sinai Medical Center Methods of assessing crohn's disease patient phenotype by i2, ompc and asca serologic response
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
FR2876798A1 (fr) * 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
CA2589746A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
JP4577083B2 (ja) * 2005-04-28 2010-11-10 味の素株式会社 クローン病の診断方法
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20070282714A1 (en) * 2006-04-27 2007-12-06 Snocap, Inc. System, method and computer program product for providing an e-commerce interface on a web page to facilitate e-commerce involving digital assets
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2010056682A2 (en) 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010101255A1 (ja) * 2009-03-05 2010-09-10 味の素株式会社 クローン病診断試薬
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP3309556B1 (de) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Verfahren zur diagnostizierung des reizdarmsyndroms
EP2464764A1 (de) 2009-08-14 2012-06-20 The Procter & Gamble Company Spinndüsenkopfanordnung und verfahren zur herstellung von fasern mit dieser anordnung
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
US8445215B1 (en) 2010-07-23 2013-05-21 Nestec S.A. Assays and methods for the detection of Crohn's disease
CA2827609A1 (en) 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
WO2012158831A1 (en) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
EP2904405B1 (de) 2012-10-05 2017-05-31 Nestec S.A. Verfahren zur vorhersage und überwachung von mukosale heilung
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
WO2017079653A2 (en) 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5681699A (en) 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5932429A (en) * 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6218129B1 (en) * 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

Also Published As

Publication number Publication date
US20090221006A1 (en) 2009-09-03
US7993867B2 (en) 2011-08-09
US20070161065A1 (en) 2007-07-12
US7138237B1 (en) 2006-11-21
WO2001089361A2 (en) 2001-11-29
DE60112744T2 (de) 2006-06-14
ES2247115T3 (es) 2006-03-01
EP1285271A2 (de) 2003-02-26
DE60112744D1 (de) 2005-09-22
JP4917728B2 (ja) 2012-04-18
EP1285271A4 (de) 2003-07-23
US7993865B2 (en) 2011-08-09
WO2001089361A3 (en) 2002-03-28
EP1285271B1 (de) 2005-08-17
US20090221007A1 (en) 2009-09-03
US7993866B2 (en) 2011-08-09
JP2004526122A (ja) 2004-08-26
AU2001261741A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
DE69318420D1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
EP1180938A4 (de) Agentien, zusammensetzungen und verfahren zur diagnose und/oder behandlung oder vorbeugung von plaquebildenden erkrankungen
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
WO2002084249A3 (en) Therapeutic and diagnostic uses of antibody specificity profiles
DE60236646D1 (de) Anti-VEGF-2 Antikörper
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
EP2277917A3 (de) B7-H3L-Flächen-Target und Antikörperfamilie, die dieses Target erkennt
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
BG101024A (bg) Моноклонално антитяло срещу сd44v6
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
WO2002041842A3 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
DE69329642D1 (de) Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0006437D0 (en) Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE69524242D1 (de) Breit-reaktive opsonische antikörper, die mit gemeinsamen staphylococcus-antigenen reagieren
DE69814078D1 (de) Verbessertes Verfahren zur Bestimmung von Allergien
DE60127935D1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
ATE283282T1 (de) Epitope des shigella-artigen toxins und ihre verwendung als impfstoff und in der diagnose
WO2000049409A3 (en) ASSAY FOR THE IDENTIFICATION OF IgE ANTIBODY SUPPRESSORS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties